Neuroone Medical Technologies Corp (NMTC)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $6.78M
Last updated: Nov 17, 2026 at 4:15 PM ET
Neuroone Medical Technologies Corp (NMTC) Statistics
Neuroone Medical Technologies (NMTC) has a market cap of $6.78M and an enterprise value of $4.81M. It kept -71.51% of revenue as net income over the last 12 months. Revenue grew 50.82% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 29.10% below the market cap, as cash exceeds debt.
| Market Cap | $6.78M |
|---|---|
| Enterprise Value | $4.81M |
| Latest price (Nov 17, 2026) | $0.71 |
Key Dates
The next earnings report is set for Dec 15, 2026, after the close.
| Next Earnings Date | Dec 15, 2026, after the close |
|---|---|
| Last Earnings Date | Aug 13, 2026 |
| Fiscal Year End | September |
Valuation Ratios
Sales and book value multiples are 0.6x and 1.6x.
| P/S Ratio | 0.6x |
|---|---|
| Forward P/S | 0.5x |
| P/B Ratio | 1.6x |
| P/TBV Ratio | 1.7x |
Price Statistics
The stock is down 82.92% over 52 weeks and trades 34.26% below its 50-day average.
| Beta (1Y) | 0.80 |
|---|---|
| 52-Week Change | -82.92% |
| 1-Month Change | -29.34% |
| 3-Month Change | -67.59% |
| 6-Month Change | -82.81% |
| 5-Year Change | -94.52% |
| Total Return (1Y) | -82.92% |
| Total Return (3Y CAGR) | -55.25% |
| Total Return (5Y CAGR) | -45.61% |
| Max Drawdown (1Y) | -87.99% |
| Max Drawdown (3Y) | -93.87% |
| Sharpe Ratio (1Y) | -2.01 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $1.08 |
| 200-Day Average | $2.93 |
| 52-Week Range | $0.74 to $6.12 |
| RSI (14 Days) | 30.9 |
| Average Volume (20 Days) | 65.55K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.84x current liabilities, and total debt is 0.02x shareholder equity.
| Current Ratio | 2.84x |
|---|---|
| Quick Ratio | 1.71x |
| Debt / Equity | 0.02x |
Returns and Efficiency
Return on invested capital is -147.05% and return on equity is -189.76% over the last 12 months.
| Return on Equity (ROE) | -189.76% |
|---|---|
| Return on Assets (ROA) | -115.57% |
| Return on Invested Capital (ROIC) | -147.05% |
| Asset Turnover | 1.18x |
| Inventory Turnover | 2.13x |
| Receivables Turnover | 5.67x |
| Cash Conversion Cycle | 160 days |
Scores
NMTC has an Altman Z-Score of -19.05, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -19.05 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $10.00M over the last 12 months.
| Revenue | $10.00M |
|---|---|
| Revenue Growth (YoY) | +50.82% |
| Gross Profit | $5.57M |
| Operating Income | -$7.60M |
| Pretax Income | -$7.15M |
| Net Income | -$7.15M |
| EBITDA | -$6.91M |
| Reported EPS (TTM) | -$0.74 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 60.90% of the $6.19M in total assets.
| Cash and Equivalents | $2.05M |
|---|---|
| Total Debt | $73.32K |
| Net Cash | $1.97M |
| Net Cash Per Share | $0.23 |
| Working Capital | $3.75M |
| Shareholder Equity | $3.77M |
| Book Value Per Share | $0.43 |
| Tangible Book Value | $3.74M |
| Tangible Book Per Share | $0.43 |
| Total Assets | $6.19M |
| Total Liabilities | $2.42M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $109.54K of capital spending, operating cash flow left -$7.16M of free cash flow.
| Operating Cash Flow | -$7.05M |
|---|---|
| Capital Expenditures | $109.54K |
| Free Cash Flow | -$7.16M |
| FCF Per Share | -$0.79 |
| Depreciation and Amortization | $236.88K |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -76.05%.
| Gross Margin | 55.67% |
|---|---|
| Operating Margin | -76.05% |
| Pretax Margin | -71.51% |
| Net Margin | -71.51% |
| EBITDA Margin | -69.14% |
| FCF Margin | -71.63% |
| Gross Margin (5Y Average) | 5.14% |
Growth
Revenue grew 313.45% a year over 3 years.
| Revenue Growth (3Y CAGR) | +313.45% |
|---|---|
| Revenue Growth (5Y CAGR) | +44.41% |
| Book Value Per Share Growth (2Y CAGR) | -18.58% |
| Tangible Book Per Share Growth (2Y CAGR) | -18.25% |
Dividends and Yields
NMTC does not pay a dividend. Its free cash flow yield is -115.97%.
| FCF Yield | -115.97% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-6 reverse split on Apr 16, 2026.
| Last Split Date | Apr 16, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Peer Position
Against 7 similar companies, NMTC has the 4th highest P/S.
P/S RatioPeer median 0.6x
ROICPeer median -164.51%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +18.57%
| P/S Ratio | 0.6x vs 0.6x median |
|---|---|
| ROIC | -147.05% vs -164.51% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +50.82% vs +18.57% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NMTC
What is NMTC's market cap?
Neuroone Medical Technologies has a market cap of $6.78M. Its enterprise value, which adds debt and subtracts cash, is $4.81M.
How many shares of NMTC are outstanding?
Neuroone Medical Technologies has 8.74M shares outstanding. The count is up 7.88% from a year earlier.
Does NMTC pay a dividend?
No. Neuroone Medical Technologies does not pay a dividend.
How much debt does NMTC have?
Neuroone Medical Technologies has $73.32K of total debt and $2.05M of cash and equivalents, a net cash position of $1.97M.
NMTC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors